olmesartan has been researched along with leucine in 2 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (leucine) | Trials (leucine) | Recent Studies (post-2010) (leucine) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 28,515 | 744 | 4,178 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cheng, XW; Izawa, H; Kim, W; Kobayashi, M; Kuzuya, M; Murohara, T; Nagata, K; Nishizawa, T; Obata, K; Okumura, K; Sasaki, T; Sato, K; Shi, GP; Yamada, T; Yokota, M | 1 |
2 other study(ies) available for olmesartan and leucine
| Article | Year |
|---|---|
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cathepsins; Cells, Cultured; Fibrosis; Heart Failure; Humans; Hypertension; Imidazoles; Leucine; Myocardium; Myocytes, Cardiac; NADPH Oxidases; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Sodium Chloride; Superoxides; Tetrazoles; Ventricular Remodeling | 2008 |